Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $290
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $280 to $290.
October 09, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's price target has been raised from $280 to $290 by Oppenheimer, maintaining an Outperform rating.
The raised price target indicates that the analyst believes Amgen's stock has potential for further growth. This is likely to have a positive impact on the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100